Epi Biologics
San Mateo, US · Founded 2021 · 50 employees on LinkedIn · 10 known investors
Find your way into Epi Biologics
Epibiologics develops protein degradation medicines using protein sciences and antibody engineering capabilities.
Founders & leadership
AL
Ann Lee-KarloninCEO, President, and Board Member
MM
Mitchell MutzNamed on SEC filing
JW
James WellsNamed on SEC filing
Board
SB
AC
SM
MK
Michael KavanaughFounding Advisor
JC
Jason ColomaBoard director
Investors · 10
Avego BioScience CapitalAlpharetta
GV (Google Ventures)Mountain View · $250K – $50M
Mission BiocapitalSan Francisco · $500K
Novartis Venture FundBasel · $5M – $25M
Roche Venture FundBasel · $648K – $3.2M
Samsara BioCapitalPalo Alto
Taiho Ventures, LLCMenlo Park
Vivo CapitalPalo Alto · $10M – $50M
Digitalis VenturesreportedNew York · $100K – $10M
Polaris PartnersreportedBoston · $500K – $5Mvia Alexandra Cantley · board
Reported raises · per SEC filings
Form D private placements$73M disclosed across 1 round · 2022
▶$73MraisedApr 2024 · 15 investors · BiotechnologyRule 506(b)
▶$73MraisedApr 2024 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jason ColomaDirector
- Ann Lee-KarlonExecutive Officer, Director
- Samuel BjorkDirector
- Alexandra CantleyDirector
- Mitchell MutzExecutive Officer, Director
- Seiji MiyaharaDirector
- James WellsDirector
- Offering amount
- $73M
- Amount sold
- $73M
- First sale
- Mar 2022
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 6
by search overlap
Abiologics32 shared keywordsAbiologics uses computational design tools to create protein-inspired molecules called Synteins, engineered to avoid the vulnerabilities of natural protein medicines while retaining biological function. The company develops these molecules as a new class of therapeutics with the aim of advancing candidates toward clinical development.
Peptilogics24 shared keywordsPeptilogics is a clinical-stage surgical therapeutics company developing zaloganan (PLG0206), a novel anti-biofilm drug to treat and prevent medical device-related infections such as prosthetic joint infections. Its lead candidate is in a pivotal Phase 2/3 trial and holds FDA Orphan Disease, Fast Track, and QIDP designations.
Bioworld22 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Epicrispr Biotechnologies21 shared keywordsEpic CRISPR develops GEMS (Gene Expression Modulation System), a modular epigenetic editing platform that combines DNA-binding proteins, guide RNAs, and modulator proteins to create genetic medicines. The company serves the biotech/medtech sector with advanced tools for precise gene expression control and disease treatment.
Epics Therapeutics19 shared keywordsEPICS Therapeutics develops RNA epigenetics-based cancer treatments, focusing on METTL3 inhibitors for cancers including non-small cell lung cancer, pancreatic cancer, ovarian cancer, and colorectal cancer where existing therapies are insufficient.
Eli Lilly18 shared keywordsEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.
Companies competing with Epi Biologics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Epi Biologics do?
- Epibiologics develops protein degradation medicines using protein sciences and antibody engineering capabilities.
- Who are Epi Biologics's investors?
- Epi Biologics's investors include Avego BioScience Capital, GV (Google Ventures), Mission Biocapital, Novartis Venture Fund, Roche Venture Fund, Samsara BioCapital, Taiho Ventures, LLC, Vivo Capital and 2 more.
- How much funding has Epi Biologics raised?
- Epi Biologics has disclosed $73M raised across 1 round.
- Where is Epi Biologics headquartered?
- Epi Biologics is headquartered in San Mateo, US.